Here are the 424B prospectus supplements from Check-Cap Ltd. (CHEK) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CHEK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CHEK filings page.
Check-Cap Ltd. files a Prospectus Supplement registering up to 2,267,857 Ordinary Shares as part of its existing prospectus dated February 23, 2026. This supplement incorporates by reference a Form 6-K furnished February 24, 2026 and updates the Registration Statement on Form F-1.
The attached Form 6-K states that MBody AI Corp. has submitted a Nasdaq listing application, described as a regulatory milestone toward closing the previously announced merger with Check-Cap, which the companies target to close in the first half of 2026, subject to customary closing conditions. The press release also notes a $30M growth facility is available. The supplement must be read with the Prospectus and Risk Factors referenced therein.
Check-Cap Ltd. is registering for resale 2,267,857 Ordinary Shares pursuant to a prospectus dated February 23, 2026. This total includes 2,000,000 Ordinary Shares issuable under a purchase agreement and 267,857 Commitment Fee Shares issued as consideration.
The shares relate to a Purchase Agreement dated December 17, 2025 under which Check-Cap may, at its option, sell and issue up to $30.0 million of Ordinary Shares to ARC Group International Ltd. over three years. The company will not receive proceeds from resale by the Selling Shareholder; the company may receive proceeds only if it elects to sell shares to the Selling Shareholder under the Purchase Agreement.
As context, there were 7,288,359 Ordinary Shares outstanding as of January 29, 2026. The Purchase Agreement contains ownership limits including a 9.99% beneficial ownership cap for the Selling Shareholder and an Exchange Cap of 19.99% of outstanding Ordinary Shares as of the Purchase Agreement date, subject to shareholder approval or Nasdaq exception.